Rankings
▼
Calendar
RIGL Q1 2024 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$541M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$30M
+13.3% YoY
Gross Profit
$28M
93.1% margin
Operating Income
-$7M
-23.6% margin
Net Income
-$8M
-27.9% margin
EPS (Diluted)
$-0.47
QoQ Revenue Growth
-17.5%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$127M
Total Liabilities
$158M
Stockholders' Equity
-$32M
Cash & Equivalents
$26M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$30M
$26M
+13.3%
Gross Profit
$28M
$25M
+9.6%
Operating Income
-$7M
-$13M
+45.3%
Net Income
-$8M
-$14M
+39.1%
Revenue Segments
Gross product sales
$38M
69%
Product sales, net
$26M
47%
Revenues from collaborations
$4M
6%
Discounts and allowances
-$12M
-22%
← FY 2024
All Quarters
Q2 2024 →